MedTrace Logo

The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers

NCT06937814 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-03-09

No results posted yet for this study

Summary

The goal of this double-blind, randomized placebo-controlled study is to evaluate the effect of an 8-week supplementation of Humiome ® Post LB (170 mg) on bowel movements in healthy adult volunteers compared to Placebo adjusted on baseline. The main question\[s\] it aims to answer \[is/are\]:

Does Humiome ® Post LB improve bowel movements with self-reported GI issues?

Participants will be provided Humiome ® Post LB (170 mg) for 8 weeks and asked to complete a study diary, questionnaires, and stool samples.

Conditions

  • GI Issues
  • Bowel Movements
  • Gastrointestinal Symptoms

Interventions

DIETARY_SUPPLEMENT

Humiome ® Post LB

Participants will be instructed to take one capsule with a glass of water after the first meal of the day.

OTHER

Placebo

Participants will be instructed to take one capsule with a glass of water after the first meal of the day.

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • DSM Nutritional Products, Inc.

    lead INDUSTRY

Principal Investigators

  • David Crowley, MD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-16
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06937814 on ClinicalTrials.gov